Risk Factors Update Summary

• The company is currently not in compliance with NYSE American listing standards, risking delisting. This could significantly impact investor confidence and stock value.
• The company reported a net loss of $29 million for the year ended June 30, 2024, compared to $27 million in 2023. This change might result in increased investor concern regarding profitability.
• The Company anticipates incurring significant expenses in the future, increasing from $27 million to $29 million for marketing and distribution capabilities for Vyleesi.
• The Chairman received **16,000** restricted stock units and an option for **23,000** shares, with an exercise price of **$1.83** per share.
• The company adopted a clawback policy effective for compensation granted after April 1, 2019. This policy may result in significant financial recoveries from executives based on restated financial results.
• As of June 30, 2024, the accumulated deficit increased to $441 million from $415 million in 2023. This change indicates worsening financial health.
• The Company may receive contingent, sales-based milestone payments of up to $159 million from Cosette Pharmaceuticals based on Vyleesi sales.
• On December 19, 2023, the company recorded a gain of $7,781,844 from the sale of Vyleesi. This substantial gain may influence future financial stability and investor outlook.
• The company recorded stock-based compensation related to stock options of $873,000 for 2024, up from $633,000 in 2023. This change might result in increased investor confidence.
• Annual retainer for the Chairman increased from **$87,000** to **$109,000**, while other directors' retainer rose from **$40,000** to **$50,000**.
• The company initiated a Phase 2 clinical study for obesity treatment in August 2024, enrolling up to 60 patients. This change could significantly impact future revenue potential.
• The fair value of option grants increased from $2.68 to $0.82 for the year ended June 30, 2024. This change might indicate improved financial health.
• The Company recorded an adjustment of $1,850,544 million for warrants misclassified as equity, impacting financial statements significantly.
• All 10b5-1 plans must be approved in writing by the Chief Financial Officer in advance. This change enhances oversight and compliance regarding insider trading policies.
• The company has issued 943,145 shares upon exercise of warrants at an exercise price of $2.12 per share. This increase in shares could dilute existing shareholder value.
• The Company expects existing cash and cash equivalents of $9 million to fund operating expenses through the second half of 2024.
• The company reported state NOL carryforwards of approximately $181,000,000 for 2024, an increase from $155,000,000 in 2023. This change might enhance tax planning strategies.
• The maximum civil penalties for insider trading violations can reach $1 million or three times the profit gained. This change emphasizes the serious financial consequences of noncompliance.
• The company expects to incur substantial net losses as it continues to develop its product candidates, including bremelanotide and PL9643. This change highlights ongoing financial risks.
• The company has recognized $4,490,090 in product revenue for fiscal 2024, a decrease from $4,850,678 in fiscal 2023. This decline may raise concerns about revenue generation.
• The number of equity compensation plans approved by security holders increased from **2** to **3**, indicating a broader incentive structure.
• The Company has accrued $1,509,797 in clinical and regulatory costs, reflecting increased operational expenses compared to previous filings.
• The valuation allowance increased by $11,193,000 for 2024, compared to $5,653,000 in 2023. This change might indicate potential challenges in realizing deferred tax assets.
• The company has until April 10, 2025, to regain compliance with NYSE American standards, which may require significant operational adjustments and funding.
• The company may face significant competition in the obesity treatment market from major pharmaceutical companies, which could adversely affect its market position.
• Audit fees for fiscal **2024** increased to **$504,000**, up from **$491,000** for fiscal **2023**, reflecting higher compliance costs.
• The company withheld shares valued at $56,401 for tax obligations in 2024, up from $16,191 in 2023. This change might affect cash flow management strategies.
• The company’s Insider Trading Policy now includes stricter pre-clearance provisions for Restricted Persons, enhancing compliance measures.